New Crohn's Disease Findings from University of Cambridge Discussed (Not all monoclonals are created equal - Lessons from failed drug trials in Crohn's disease)
By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Gastroenterology. According to news originating from Cambridge, United Kingdom, by NewsRx editors, the research stated, "The recent success of the anti-integrin antibody Vedolizumab can barely conceal the fact that the biologics armamentarium in Crohn's disease has barely evolved beyond TNF blockers so far. This contrasts with other immune-related diseases considered mechanistically and genetically closely related, such as psoriasis and rheumatoid arthritis, where approved biologics target a variety of independent biological mechanisms."
Our news journalists obtained a quote from the research from the University of Cambridge, "Several pharmacological assets that entered clinical development have proven ineffective, or less effective than originally anticipated. While blockade of IL-17A and its receptor via Secukinumab and Brodalumab, respectively, worsened Crohn's disease, the beneficial effect of IL-12/23 p40 blockade via Ustekinumab appeared confined to a subpopulation of Crohn's disease patients who have previously failed on TNF blockers. Clinical development of the IFN gamma blocker Fontolizumab was stopped despite demonstrating some clinical benefit, while the T cell co-stimulation blocker Abatacept did not exhibit any hint towards efficacy in Crohn's disease. Here I review results from these individual development programmes, and also reflect on the lack of efficacy of the TNF blocker Etanercept. I will discuss aspects of individual trials that might have confounded their interpretation and highlight the evolution in primary and secondary end-points that have contributed to increasing robustness of results obtained in recent years."
According to the news editors, the research concluded: "Finally, I suggest that mechanistic studies in murine genetic models combined with exploratory immunological studies incorporated in early drug development may represent the key for identifying the next generation of successful pharmacological targets in Crohn's disease."
For more information on this research see: Not all monoclonals are created equal - Lessons from failed drug trials in Crohn's disease. Best Practice & Research in Clinical Gastroenterology, 2014;28(3):437-449. Best Practice & Research in Clinical Gastroenterology can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England (see also Gastroenterology).
The news correspondents report that additional information may be obtained from A. Kaser, University of Cambridge, Addenbrookes Hospital, Dept. of Med, Div Gastroenterol & Hepatol, Cambridge CB2 1TN, United Kingdom.
Keywords for this news article include: Europe, Therapy, Genetics, Cambridge, Pharmacology, United Kingdom, Crohn's Disease, Gastroenteritis, Gastroenterology, Digestive System Diseases, Gastrointestinal Diseases, Inflammatory Bowel Diseases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC